Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.13 and traded as high as $0.17. Enzon Pharmaceuticals shares last traded at $0.15, with a volume of 99,772 shares.
Enzon Pharmaceuticals Stock Down 5.2 %
The firm’s 50-day simple moving average is $0.13 and its 200-day simple moving average is $0.13. The firm has a market capitalization of $10.20 million, a PE ratio of 13.76 and a beta of 0.27.
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.
Read More
- Five stocks we like better than Enzon Pharmaceuticals
- Where to Find Earnings Call Transcripts
- Oracle Announces Game-Changing News for the AI Industry
- Comparing and Trading High PE Ratio Stocks
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Calculate Options Profits
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
